LRIG1-2 and LMO7 immunoreactivity in vulvar squamous cell carcinoma: Association with prognosis in relation to HPV-DNA and p16 (INK4a) status

• Published in: Oncology reports Vol. 42; no. 1; p. 142
• Main Authors: Stefansson, Kristina, Oda, Husam, Ofverman, Charlotte, Lundin, Eva, Hedman, Hakan, Lindquist, David
• Format: Journal Article
• Language: English
• Published: Spandidos Publications 01.07.2019
• Subjects: Analysis; Antibodies; Cancer; Carcinoma; DNA; EDTA; Health aspects; Immunoglobulins; Immunohistochemistry; Medical equipment industry; Papillomavirus infections; Prognosis; Retirement benefits; Scientific equipment industry; Squamous cell carcinoma; Tumors; United States; Sweden
• ISSN: 1021-335X; 1791-2431
• DOI: 10.3892/or.2019.7138

The present study was conducted to investigate the possible prognostic value of molecular markers LRIG1-2 and LIM domain 7 protein (LMO7) in vulvar squamous cell carcinoma (VSCC) and their possible correlation to human papilloma virus (HPV)- and p16 (INK4a)-status of the tumors. Patients diagnosed with VSCC at the University Hospital of Umea, Sweden, during the years 1990-2013 were selected. Tumor blocks were retrieved from tissue archives and clinical data were collected from the records of patients. HPV-PCR analysis, HPV genotyping and immunohistochemistry were performed. In total, 112 patients were included. Forty percent of the tumors were HPV-positive, 27% were p16 (INK4a)-positive and 23% were positive for both HPV and p16 (INK4a) (considered HPV-driven). HPV-positivity and p16 (INK4a)-positivity were associated with prolonged disease-free survival (DFS) in Kaplan-Meier survival analysis. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) immunoreactivity was not significantly associated with survival. High leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2) immunoreactivity was associated with a prolonged overall survival (OS) (P=0.001). By analyzing HPV-negative cases only, it was determined that high LRIG2 immunoreactivity was associated with both favorable OS (P=0.008) and DFS (P=0.031). LRIG2 immunoreactivity was also an independent prognostic factor in multivariate analysis of OS (P=0.002, HR=0.41; 95% CI, 0.24-0.71). High immunoreactivity with LMO7-1250 antibody was associated with survival benefits in the whole cohort (OS; P=0.011) although DFS was only prolonged in HPV-negative and not HPV-driven tumors (P=0.038 and 0.042, respectively). The present study indicated that LRIG2 and LMO7 may be useful prognostic markers in VSCC, particularly for patients without HPV-driven tumors or with advanced tumors at diagnosis. In contrast to earlier observations regarding other types of squamous cell carcinoma, LRIG1 was not a significant prognostic factor in VSCC.